Lobe Sciences Ltd. and Cynaptec Pharmaceuticals, Inc. to Present a New Therapeutic Approach for the Treatment of Chronic Cluster Headaches at Clusterbusters 2025

Executive Summary

• Lobe Sciences Ltd. announces its participation in the Clusterbusters 20th Annual U.S. Patient Conference (September 11-14, 2025, in Grapevine, Texas) to engage with the cluster headache community and advocate for its lead asset.
• Dr. Fred D. Sancilio, Chairman and CEO, will discuss ongoing research by subsidiary Cynaptec Pharmaceuticals regarding L-130 (Conjugated Psilocin™), a potential treatment for Chronic Cluster Headaches.
• The company highlights a recent $6M funding secured for Cynaptec, with an option for an additional $20M to complete US FDA submission, and aims to establish a patient advocacy team to help design meaningful clinical endpoints.

Key Details

• Conference Details: Participation in the Clusterbusters 20th Annual U.S. Patient Conference, a key event for the cluster headache community involving patients, caregivers, and healthcare professionals.
• Leadership Engagement: Dr. Fred D. Sancilio (Chairman and CEO) will present on research conducted by Cynaptec Pharmaceuticals, Inc.
• Asset Focus: L-130 (Conjugated Psilocin™) is being studied as a potential treatment for Chronic Cluster Headaches; it is a novel, patented, oral, stable analog of psilocin designed to enhance bioavailability and therapeutic efficacy.
• Funding Context: Lobe recently secured $6M in funding for Cynaptec Pharmaceuticals, with an investor option for up to an additional $20M to complete the US FDA submission of L-130.
• Strategic Goals: The company aims to build a bridge to patients and establish a patient advocacy team to incorporate firsthand disease experience into the design of future clinical studies.
• Company Structure: Lobe Sciences operates through two subsidiaries:
  • Cynaptec Pharmaceuticals, Inc.: Advancing Conjugated Psilocin (CP) for Chronic Cluster Headache (seeking orphan indication); Substance use disorder (SUD) and other CNS disorders are under strategic review.
  • Altemia, Inc.: Addressing sickle cell disease with a medical food in early-stage distribution and S-100, a patent-pending therapeutic candidate.

Notable Quotes

• "For 25 years, Clusterbusters has been leading research and education on the use of psychedelics to treat cluster headache. We welcome Lobe Sciences and Cynaptec Pharmaceuticals to our conference to share their work developing conjugated psilocin as a treatment for chronic cluster headache. This medicine has great potential to better manage debilitating cluster headaches, and we support their expedited pathway to bring patients relief as soon as possible." -- Bob Wold, Founder and Executive Director of Clusterbusters
• "We've been working with the leadership of Clusterbusters for over a year and they've been instrumental in sharing patient experiences with this devastating condition. Our goal at this conference will be to build a wider bridge to patients and establish a patient advocacy team that can help us design meaningful clinical endpoints, with firsthand experience with the disease." -- Dr. Fred D. Sancilio, Chairman and CEO of Lobe Sciences Ltd.